Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment By Ogkologos - June 16, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-9 study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR 4 Ways to Avoid Comparing Yourself to Others on Social Media... October 31, 2023 Can Using Hair Dyes or Hair Relaxers Impact Your Cancer Risk? July 13, 2023 As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... October 16, 2024 Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab February 4, 2021 Load more HOT NEWS When Cancer Isn’t Your Only Challenge: How I Learned to Cope Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of...
